Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31858 in Non-cystic Fibrosis Bronchiectasis (Phase II)
CTR20222844Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing HSK31858 tablets with Placebo (HSK31858-matched) (2 arms). Primary endpoint: Incidence of acute bronchiectasis exacerbations within 24 weeks. Started Nov 2022; status: completed.
02
Drugs
HSK31858
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on CTR20222844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222844.